Table 2 Dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy
Nature of event | Events | Time to event (months) | Events during treatment | Major events | Histology | DMARDsb | Prednisoloneb | Permanent withdrawal of anti-TNF-αc | |
|---|---|---|---|---|---|---|---|---|---|
No. (%) | Mediana | Range | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
Infection | 33 (25.8) | 9.1 | 1.1–61.1 | 24 (73) | 0 | 5 (15) | 20 (61) | 21 (64) | 4 (12) |
Eczema | 20 (15.6) | 7.1 | 0.2–49.9 | 16 (80) | 1 (5) | 4 (20) | 8 (40) | 7 (35) | 3 (15) |
Drug-related eruption | 15 (11.7) | 1.9 | 0.1–18.8 | 15 (100) | 1 (7) | 12 (80) | 6 (40) | 6 (40) | 7 47) |
Ulcers | 9 (7.0) | 13.6 | 0.3–52.5 | 3 (33) | 1 (11) | 2 (22) | 7 (78) | 4 (44) | 1 (11) |
Skin tumor, benign | 7 (5.5) | 12.9 | 2.0–18.1 | 7 (100) | 0 | 2 (29) | 5 (71) | 4 (57) | 0 |
Skin tumor, malignant | 5 (3.9) | 4.5 | 1.1–38.0 | 4 (80) | 0 | 5 (100) | 2 (40) | 2 (40) | 1 (20) |
Xerosis cutis | 6 (4.7) | 8.9 | 4.2–26.3 | 6 (100) | 0 | 1 (16) | 4 (67) | 1 (17) | 1 (17) |
Vasculitis | 5 (3.9) | 12.0 | 1.5–49.9 | 4 (80) | 0 | 4 (80) | 3 (60) | 5 (100) | 1 (20) |
Actinic keratosis | 5 (3.9) | 26.3 | 4.5–112.9 | 2 (40) | 0 | 3 (60) | 5 (100) | 2 (40) | 0 |
CVI/varices | 4 (3.0) | 24.0 | 1.7–33.6 | 3 (75) | 0 | 0 | 3 (75) | 2 (50) | 0 |
Psoriasis/psoriasiform | 3 (2.3) | 15.5 | 8.4–50.1 | 3 (100) | 0 | 3 (100) | 0 | 2 (67) | 1 (33) |
Edema | 3 (2.2) | 8.2 | 4.0–39.6 | 2 (67) | 0 | 1 (33) | 1 (33) | 1 (33) | 0 |
Stasis dermatitis | 3 (2.2) | 17.5 | 14.6–42.1 | 3 (100) | 0 | 1 (33) | 1 (33) | 1 (33) | 0 |
Seborrheic dermatitis | 2 (1.5) | 0.4, 19.8 | – | 2 (100) | 0 | 0 | 0 | 0 | 0 |
Other event | 8 (6.0) | 5.0 | 1.9–25.9 | 6 (75) | 0 | 4 (50) | 4 (50) | 2 (25) | 2 (25) |
Total | 128 (100) | 9.1 | 0.1–112.9 | 100 (78) | 3 (2) | 47 (37) | 69 (54) | 60 (47) | 21 (16) |